UB-612 COVID-19 Vaccine Uses, Dosage, Side Effects and more
The UB-612 COVID-19 Vaccine COVID-19 vaccine was developed by United Biomedical Inc Asia in Taipei as the first COVID-19 “multi-tope” protein-peptide vaccine made up of eight rationally designed components. The vaccine incorporates a strong S1-RBD component linked to a single chain fragment region (sFC) of a human IgG1, which facilitates cell attachment and acts as the principal neutralizing domain of the virus. In addition, the vaccine contains a proprietary peptide UBITh®1a for enhanced immunogenicity, five identified peptides with Th or CTL epitopes to improve peptide solubility, and aluminum phosphate adjuvant. This vaccine was designed to induce a broad immune response. It was able to reduce viral load and prevent COVID-19 infection in a mouse challenge model and in rhesus macaques. In rats, toxicity studies have so far shown favourable safety for this vaccine, Phase 1 trial is currently ongoing in Taiwan (NCT04545749).
| Attribute | Details |
|---|---|
| Trade Name | UB-612 COVID-19 Vaccine |
| Generic | UB-612 |
| UB-612 Other Names | UB-612 COVID-19, UB-612 COVID-19 vaccine |
| Type | |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | January 7, 2025 at 1:49 am |
